Compositions and methods for localized delivery of pharmaceutical agents for treating cancer - Patents.com
A topical combination of T cell and innate immune activators like calcipotriene and imiquimod provides synergistic antitumor activity against non-keratinocyte skin cancers and melanoma, enhancing immune activation and reducing tumor growth without significant side effects, offering an effective alternative to surgical resection.
Patent Information
- Application Number
- JP2021500148
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-10-03
- Filing Date
- 2019-07-02
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2039-07-02
AI Technical Summary
There are several skin malignancies that are considered poor candidates for surgical resection due to their location, extent of disease, and associated morbidity, and current systemic treatments like radiation and chemotherapy provide no significant benefit with substantial side effects.
A combination therapy using T cell activating agents such as calcipotriene or retinoic acid, and innate immune cell activators like imiquimod, TLR agonists, or STING agonists is applied topically to induce synergistic antitumor activity against non-keratinocyte skin cancers and melanoma, enhancing immune activation and tumor destruction.
The combination therapy effectively reduces or eliminates cutaneous malignancies by inducing potent adaptive immunity, reducing tumor weight synergistically, and minimizing the need for surgical intervention with fewer side effects compared to traditional treatments.
Smart Images

Figure 0007595564000004 
Figure 0007595564000005 
Figure 0007595564000006
Abstract
Description
[Technical field]
[0001] Priority claim This application claims the benefit of U.S. Provisional Application No. 62 / 694,100, filed July 5, 2018; and No. 62 / 740,514, filed October 3, 2018, all of which are incorporated herein by reference.
[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with Government support under Grant No. OD021353 awarded by the National Institutes of Health. The Government has certain rights in the invention.
[0003] The present invention relates, at least in part, to compositions (e.g., topical compositions) comprising a thymic stromal lymphopoietin (TSLP) inducer (e.g., calcipotriene) and an innate immune activator (e.g., imiquimod, TLR agonists, STING agonists and oncolytic viruses), and methods of use thereof to treat malignancies including, for example, skin cancer (e.g., Merkle cell carcinoma, melanoma, extramammary Paget's disease, cutaneous T-cell lymphoma (CTCL)], breast cancer (primary and chest wall metastases) and other cancers. [Background technology]
[0004] There are several cutaneous malignancies that are considered poor candidates for surgical resection because of the location of the cancer, the extent of the disease, and the morbidity associated with surgery. These cutaneous malignancies include breast cancer cutaneous metastases, extramammary Paget's disease, and cutaneous melanoma (particularly in situ lesions and lentigo maligna). 1~3 Systemic treatments and radiation have been used to treat these unresectable cancers with little benefit and significant side effects. 1~3 . Summary of the Invention [Means for solving the problem]
[0005] As shown herein, the combination of one or more T cell / thymic stromal lymphopoietin (TSLP) activating agents (i.e., calcipotriene, retinoic acid) with one or more innate immune cell activating agents (i.e., imiquimod, STING agonist) results in synergistic effects that provide strong antitumor immune activation against cancer, such as non-keratinocyte skin malignancies (e.g., extramammary Paget's disease and breast metastases) and cancers of the skin, including melanoma. In particular, topical calcipotriene + imiquimod, retinoic acid + imiquimod, and calcipotriene + DMXAA treatments were significantly more effective than calcipotriene, retinoic acid, imiquimod, or DMXAA monotherapy in blocking the growth of breast cancer and melanoma. In addition, short-term topical treatment with calcipotriene + imiquimod was effective in treating extramammary Paget's disease in patients. Thus, provided herein is the combination of innate immune activators with direct T cell induction by thymic stromal lymphopoietin (TSLP) activating agents and their use in proliferation disorders, particularly skin malignancies.
[0006] Provided herein is a method of treating a proliferative disorder in the skin of a subject in need thereof, comprising administering a therapeutically effective amount of (i) an agent that activates T cells by TSLP induction and (ii) an innate immune cell activation agent, preferably directly to the site of proliferation in the skin of the subject, thereby treating the proliferative disorder in the skin of the subject. Also provided herein are agents that activate T cells by TSLP induction and innate immune cell activation agent methods for use in treating a proliferative disorder in the skin of a subject in need thereof, preferably in the absence of a cytotoxic agent.
[0007] In some embodiments, the proliferation disorder in the skin is a non-keratinocyte cancer, such as melanoma, extramammary Paget's disease, or breast cancer metastasis.
[0008] In some embodiments, the site of proliferation in the skin is a tumor.
[0009] In some embodiments, the site of growth in the skin comprises a metastasis within the chest wall of the subject.
[0010] In some embodiments, the method does not include administering a cytotoxic agent.
[0011] In some embodiments, the agent that activates T cells by TSLP induction is a vitamin D analog, such as calcipotriene or retinoic acid.
[0012] In some embodiments, the innate immune cell activating agent is a TLR agonist, a STING agonist, or an oncolytic virus.
[0013] In some embodiments, the TLR agonist is imiquimod, resiquimod, 852A, motolimod (VTX-2337); CpG-ODN; or ODN2395.
[0014] In some embodiments, the STING agonist is DMXAA, MK-1454 or ADU-S100.
[0015] In some embodiments, the oncolytic virus is talimogene laherparepvec (T-Vec).
[0016] In some embodiments, the composition comprising an agent that activates T cells through TSLP induction and the composition comprising an innate immune cell activating agent are administered simultaneously or sequentially.
[0017] In some embodiments, a single composition is administered that includes an agent that activates T cells via TSLP induction and an innate immune cell activating agent.
[0018] In some embodiments, one or both of the agent that activates T cells via TSLP induction and the innate immune cell activating agent are administered locally.
[0019] Also described herein is a method of reducing or eliminating a proliferative disorder in the skin of a subject in need thereof, the method comprising topically administering a composition comprising calcipotriene and imiquimod to a site of proliferation in the skin of the subject, thereby reducing or eliminating a proliferative disorder in the skin of the subject, wherein the proliferative disorder of the skin does not include keratinocyte carcinoma.
[0020] In some embodiments, the proliferation disorder in the skin is a cutaneous malignancy.
[0021] In some embodiments, the cutaneous malignancy is melanoma, extramammary Paget's disease, or breast cancer.
[0022] In some embodiments, the site of proliferation in the skin is a tumor.
[0023] In some embodiments, tumor weight (size) is reduced synergistically.
[0024] In some embodiments, the site of growth in the skin comprises a metastasis within the chest wall of the subject.
[0025] In some embodiments, the keratinocyte carcinoma is squamous cell carcinoma ("SCC"), basal cell carcinoma ("BCC"), or keratinocyte carcinoma.
[0026] In some embodiments, the composition comprising calcipotriene and imiquimod further comprises retinoic acid.
[0027] Additionally, described herein is a method of reducing or eliminating a proliferative disorder in the skin of a subject in need thereof, the method comprising topically administering a composition consisting essentially of calcipotriene and imiquimod to a site of proliferation in the skin of a subject diagnosed with melanoma, extramammary Paget's disease or breast cancer, thereby reducing or eliminating the proliferative disorder in the skin of the subject.
[0028] Additionally, described herein is a method of reducing or eliminating a proliferative disorder in the skin of a subject in need thereof, the method comprising topically administering to a site of proliferation in the skin of the subject a composition comprising calcipotriene and a composition comprising imiquimod, thereby reducing or eliminating a proliferative disorder in the skin of the subject, wherein the proliferative disorder of the skin does not include keratinocyte carcinoma.
[0029] In some embodiments, the composition comprising calcipotriene and the composition comprising imiquimod are administered simultaneously or sequentially.
[0030] In some embodiments, the composition comprising retinoic acid is administered either simultaneously or sequentially with the composition comprising calcipotriene and the composition comprising imiquimod.
[0031] Further described herein is a method of reducing or eliminating a proliferative disorder in the skin of a subject in need thereof, the method comprising locally administering calcipotriene and a STING agonist to a site of proliferation in the skin of the subject, thereby reducing or eliminating the proliferative disorder in the skin of the subject.
[0032] In some embodiments, calcipotriene is administered topically.
[0033] In some embodiments, the proliferation disorder in the skin is a cutaneous malignancy.
[0034] In some embodiments, the cutaneous malignancy is melanoma, extramammary Paget's disease, or breast cancer.
[0035] In some embodiments, the site of proliferation in the skin is a tumor.
[0036] In some embodiments, tumor weight is reduced synergistically.
[0037] In some embodiments, the site of growth in the skin comprises a metastasis within the chest wall of the subject.
[0038] In some embodiments, the method comprises topical application of a composition comprising 0.001-0.01%, e.g., 0.005% calcipotriene or another vitamin D analogue, and 1-10%, e.g., 5% imiquimod or another TLR agonist, or retinoic acid; in some embodiments, a single composition comprising 0.001-0.01%, e.g., 0.005% calcipotriene or another vitamin D analogue, and 1-10%, e.g., 5% imiquimod or another TLR agonist is used.
[0039] In some embodiments, the compositions described herein are ointments, salves, gels, or creams.
[0040] In some embodiments, when two compositions are used, one composition is applied locally (e.g., a TSLP inducer) and the other composition is administered by injection, e.g., intralesional / intratumoral injection (e.g., a STING agonist).
[0041] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present application, including definitions, will control.
[0042] As used herein, a "subject" is a vertebrate including any member of the mammalian class, including humans, livestock and farm animals, and zoo, sports or pet animals such as mice, rabbits, pigs, sheep, goats, cows and higher primates.
[0043] As used herein, the terms "treat," "treating," "treatment," and the like refer to reducing or ameliorating a disorder and / or symptoms associated therewith. It will be understood that, although not excluded, treating a disorder or condition does not require the complete elimination of the disorder, condition, or symptoms associated therewith.
[0044] Ranges provided herein are understood to be shorthand for all values within the range, for example, the range 1 to 50 is understood to include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, or any number, combination of numbers, or subranges thereof (and fractions thereof unless the context clearly dictates otherwise).
[0045] As used herein, references to synergy or synergistic effect, including "synergistic reduction in tumor weight," refer to greater than the additive effect expected from the use of two or more therapeutic agents in combination.
[0046] As used herein, "reduction" or "reducing" is an amount that is at least about 0.05-fold less (e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 1, 5, 10, 25, 50, 100, 1000, 10000-fold or less) than an untreated control or reference standard. "Reduction" or "reducing" can also refer to an amount that is at least about 5% less (e.g., 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, or 100% or less) than an untreated control or reference standard.
[0047] Unless otherwise stated or clear from the context, the term "about" is understood herein to be within the normal tolerance limits of those skilled in the art, for example, within 2 standard deviations of the mean. "About" is understood to be within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term about.
[0048] In this disclosure, "comprises," "comprising," "containing," "having," and the like, can have the meaning ascribed to them in U.S. Patent Law and can mean "includes," "including," and the like; "consisting essentially of" or "consisting essentially of" likewise have the meaning ascribed to them in U.S. Patent Law and the terms are open-ended and take into consideration other recited entities, but exclude prior art embodiments, so long as the basic or novel characteristics recited are not altered by the other recited entities.
[0049] Other definitions are provided in context throughout this disclosure.
[0050] Other features and advantages of the invention will become apparent from the detailed description and claims. Accordingly, other aspects of the invention are set forth in the following disclosure, and are within the scope of the invention.
[0051] The following detailed description is provided by way of example and is not intended to limit the invention to the specific embodiments described, and can be understood in conjunction with the accompanying figures, which are incorporated herein by reference. [Brief description of the drawings]
[0052] [Figure 1-1]Figure 1A-D show that calcipotriene + imiquimod blocked breast cancer growth. n=4 per group; error bars represent mean + SD; two-tailed Mann-Whitney U test is used as a test of significance; scale bar: 1 cm. (1A) Schematic diagram of the experimental protocol used to determine the efficacy of calcipotriene + imiquimod as a localized immunotherapy for breast cancer. PyMTtg primary breast cancer cells are implanted subcutaneously in the groin of wild-type C57BL / 6 mice. Once tumors reached 5 mm in diameter (day 13), the following topical treatments were applied twice to the tumor site: (a) 80 nmol calcipotriene in 20 microliters 100% EtOH followed by 5% imiquimod cream, (b) 80 nmol calcipotriene in 20 microliters 100% EtOH followed by moisturizing (control) cream, (c) 20 microliters 100% EtOH followed by 5% imiquimod cream, and (d) 20 microliters 100% EtOH followed by moisturizing (control) cream. (1B) Macroscopic images of representative breast tumors within each treatment group at the endpoint showed significantly smaller tumors in calcipotriene + imiquimod treated mice compared to mice in the other groups. (1C) Tumor volume measurements over time are shown. Tumor growth is blocked by calcipotriene + imiquimod treatment (p=0.011). Arrows highlight treatment time points. (1D) Tumor weights at endpoint are shown. Breast tumors treated with calcipotriene + imiquimod were significantly smaller than those in the other treatment groups (*: p<0.05). [Figure 1-2] Figure 1E-F show that calcipotriene + imiquimod blocked breast cancer growth. n=4 per group; error bars represent mean + SD; two-tailed Mann-Whitney U test is used as a test of significance; scale bar: 1 cm. (1E) Flow cytometry analysis of breast tumors shows induction of T cells (CD3+) in calcipotriene + imiquimod-treated tumors. (1F) CD4+ and CD8+ T cells in calcipotriene + imiquimod-treated tumors are highly proliferative (Ki67+) compared to T cells isolated from tumors of other treatment cohorts. [Figure 2-1]2A-D show that calcipotriene plus STING agonist (DMXAA) blocked melanoma growth. n=3 per group; error bars represent mean + SD; two-tailed Mann-Whitney U test was used as a test of significance; scale bar: 1 cm. (2A) Schematic diagram of the experimental protocol used to determine the efficacy of calcipotriene plus DMXAA as a localized immunotherapy for melanoma. B16-F10 melanoma cells are implanted subcutaneously into the flank of wild-type C57BL / 6 mice. When tumors reached 5 mm in diameter (day 14), the following treatments were applied three times: (a) 40 nmol calcipotriene in 20 microliters 100% EtOH followed by an IP injection of 400 μg DMXAA in 100 μL saline, (b) 40 nmol calcipotriene in 20 microliters 100% EtOH followed by an IP injection of 100 μL saline, (c) 20 microliters 100% EtOH followed by an IP injection of 400 μg DMXAA in 100 μL saline, and (d) 20 microliters 100% EtOH followed by an IP injection of 100 μL saline. (2B) Macroscopic images of representative melanoma tumors within each treatment group at the endpoint showed significantly smaller tumors in calcipotriene+DMXAA treated mice compared to mice in the other groups. (2C) Tumor volume measurements over time are shown. Tumor growth is blocked by calcipotriene + DMXAA treatment (p=0.019). Arrows highlight treatment time points. (2D) End point tumor weights are shown. Calcipotriene + DMXAA treated melanoma tumors are significantly smaller than those in the other treatment groups (*: p<0.05). [Figure 2-2]Figures 2E-F show that calcipotriene plus STING agonist (DMXAA) blocked melanoma growth. n=3 per group; error bars represent mean + SD; two-tailed Mann-Whitney U test is used as a test of significance; scale bar: 1 cm. (2E) Flow cytometry analysis of melanoma tumors shows induction of T cells (CD3+) in calcipotriene + DMXAA treated tumors. (2F) CD4+ and CD8+ T cells in calcipotriene + DMXAA treated tumors are highly proliferative (Ki67+) compared to T cells isolated from tumors of other treatment cohorts. [Diagram 3]3A-D show that calcipotriene + imiquimod and retinoic acid + imiquimod blocked melanoma growth. n=3 per group; error bars represent mean + SD; two-tailed Mann-Whitney U test was used as a test of significance; scale bar: 1 cm. (3A) Schematic diagram of the experimental protocol used to determine the efficacy of calcipotriene + imiquimod and retinoic acid + imiquimod as localized combination immunotherapy for melanoma. B16-F10 melanoma cells are implanted subcutaneously into the flanks of wild-type C57BL / 6 mice. Once tumors were palpable (day 4), the following treatments were applied three times: (a) 20 nmol calcipotriene in 20 microliters 100% EtOH followed by 5% imiquimod cream, (b) 20 nmol retinoic acid in 20 microliters 100% EtOH followed by 5% imiquimod cream, (c) 20 nmol calcipotriene in 20 microliters 100% EtOH followed by moisturizing (control) cream, (d) 20 nmol retinoic acid in 20 microliters 100% EtOH followed by control cream, and (e) 20 microliters 100% EtOH followed by 5% imiquimod cream. (3B) Macroscopic images of representative melanoma tumors within each treatment group at the endpoint showed significantly smaller tumors in calcipotriene + imiquimod and retinoic acid + imiquimod treated mice compared to mice in the monotherapy groups. (3C) Tumor volume measurements over time are shown. Tumor growth is blocked by calcipotriene + imiquimod and retinoic acid + imiquimod treatments compared to imiquimod monotherapy treatment (p=0.05). Arrows highlight treatment time points (ns: not significant). (3D) End point tumor weights are shown. Melanoma tumors treated with calcipotriene + imiquimod and retinoic acid + imiquimod are significantly smaller than those in the other treatment groups (*: p<0.05; ns: not significant). [Figure 4]4A-B show that the combination of calcipotriene + imiquimod reduced EMPD lesion size in patients. (4A) Schematic diagram of the 4-day calcipotriene + imiquimod treatment used to treat two EMPD patients. (4B) Macroscopic images of EMPD lesions on the genitals of two patients before and after treatment. Note that the "after treatment" images are taken at the time of surgery. Yellow dotted lines highlight the edges of the lesions before and after treatment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0053] The present findings demonstrated that the combination of agents that activate T cells by TSLP induction (e.g., calcipotriene or retinoic acid) with innate immune cell activating agents (e.g., imiquimod, TLR agonists, STING agonists or oncolytic viruses) can produce synergistic efficacy against cancer. These combinations result in optimal activation of adaptive immunity against malignancies including breast cancer skin lesions, extramammary Paget's disease, melanoma and other lesions currently treated with imiquimod. These findings also provide a treatment modality to transform cold (non-immunogenic) cancers into hot (inflamed) cancers by combining innate signaling in myeloid cells with direct T cell stimulation by TSLP to induce potent immunity against cancer. These combination therapies destroy cancer cells (targets) by inducing optimal antigen presentation by dendritic cells and macrophages (imiquimod / DMXAA effect) and full T cell activation by detection of tumor-associated antigens (calcipotriene / retinoic acid effect). These combinations targeting signal 1, signal 2 and signal 3 for full T cell activation result in potent antitumor adaptive immunity and effective cancer treatment. While these combinations can be developed to treat internal cancers by delivering them to the tumor, the ability to deliver these agents in a local combination creates a unique opportunity to effectively treat cutaneous malignancies such as melanoma, extramammary Paget's disease and skin metastases from the breast as well as other internal cancers. Among these malignancies, extramammary Paget's disease is a rare adenocarcinoma (with a similar developmental origin as breast gland / carcinoma) of the apocrine gland-supported skin. 2 This cancer is notoriously difficult to manage. 2 Surgical recurrence rates in these patients are as high as 30% and cause significant morbidity due to the location of the lesions, most often in the groin and genitals. 13、14 In addition, there is limited data on the effectiveness of chemotherapy and radiation for this cancer. 15 Therefore, this combination may be used as an effective therapeutic approach for extramammary Paget's disease and may revolutionize the medical care of patients with this debilitating disease.
[0054] Treatment Method The methods described herein include methods for treating proliferation disorders, particularly skin malignancies.Generally, the methods include administering a therapeutically effective amount of the combination therapy described herein, i.e., a combination therapy comprising an agent that activates T cells by TSLP induction (e.g., calcipotriene or retinoic acid) and an innate immune cell activation agent (e.g., imiquimod, TLR agonist, STING agonist or oncolytic virus) to a subject who needs or is determined to need such treatment.
[0055] Generally speaking, the compositions and methods do not involve the use of cytotoxic agents, such as those described in U.S. Patent Application Publication No. 2017 / 0246299.
[0056] As used in this context, "treat" means to improve at least one symptom of a proliferation disorder. Administration of a therapeutically effective amount of a compound described herein for the treatment of a proliferation disorder may result in a decrease in the rate of lesion or tumor growth, regression of the lesion or tumor, and / or a decrease in the size of the lesion or tumor, as well as an increase in life span, a decrease in the risk of recurrence, and / or a decrease in the need for surgical intervention.
[0057] The combinations described herein are useful for treating disorders associated with abnormal apoptosis or differentiation processes, such as cell proliferation or differentiation disorders, such as cancer, for example, by generating active immunity. Examples of cell proliferation and / or differentiation disorders include cancer, such as carcinoma, sarcoma, metastatic disorders, or hematopoietic neoplastic disorders, such as leukemia. Metastatic tumors can originate from a multitude of primary tumor types, including, but not limited to, types of prostate, colon, lung, breast, and liver origin.
[0058] As used herein, the terms "cancer," "hyperproliferative," and "neoplastic" refer to cells that have the capacity for autonomous proliferation, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic disease states may be classified as pathological, i.e., characterizing or constituting a disease state, or non-pathological, i.e., deviating from normal but not associated with a disease state. The term is meant to include all types of cancerous growth or oncogenic processes, metastatic tissues, or malignantly transformed cells, tissues, or organs, regardless of histopathological type or stage of invasion. "Pathologically hyperproliferative" cells are present in disease states characterized by malignant tumor growth. An example of non-pathological hyperproliferative cells is the proliferation of cells associated with wound repair.
[0059] The term "cancer" or "neoplasm" includes malignancies of various organ systems, such as those affecting the lung, breast, thyroid, lymphatic, gastrointestinal, and genitourinary tracts, as well as adenocarcinomas, including most colorectal cancers, renal cell carcinoma, prostate cancer and / or testicular cancer, non-small cell carcinoma of the lung, cancer of the small intestine, and cancer of the esophagus.
[0060] The term "carcinoma" is recognized by those skilled in the art and refers to malignant tumors of epithelial or endocrine tissue, including respiratory, gastrointestinal, genitourinary, testicular, breast, prostate, endocrine, and melanoma. Exemplary carcinomas include those forming from tissue of the cervix, rectum, lung, prostate, breast, head and neck, colon, and ovary. The term also includes carcinosarcomas, which include, for example, malignant tumors composed of carcinomatous and sarcomatous tissue. "Adenocarcinoma" refers to carcinomas derived from glandular tissue or in which the tumor cells form recognizable glandular structures.
[0061] The term "sarcoma" is art-recognized and refers to malignant tumors of mesenchymal origin.
[0062] In some embodiments, the disorder is a cutaneous non-keratinocyte cancer, such as extramammary Paget's disease, breast cancer cutaneous metastasis, and cutaneous melanoma (eg, in situ lesions and lentigo maligna).
[0063] In some embodiments, the disorder is not a keratinocyte carcinoma, ie, not a basal cell carcinoma or a cutaneous squamous cell carcinoma (SCC).
[0064] Additional examples of proliferative disorders include hematopoietic neoplastic disorders. As used herein, the term "hematopoietic neoplastic disorders" includes diseases associated with hyperplasia / neoplastic cells of hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. Preferably, the disease is cutaneous T-cell lymphoma (CTCL).
[0065] In some embodiments, the proliferative disorder comprises a precancerous skin disorder. The skin disorder may be associated with abnormal activity of a cell or group or layer of cells in the dermis, epidermis or subcutaneous layer, or an abnormality in the dermal-epidermal junction.
[0066] Thymic stromal lymphopoietin (TSLP) inducer The combination includes the use of a TSLP inducer. As used herein, a "TSLP inducer" is any compound capable of inducing thymic stromal lymphopoietin (TSLP). TSLP is an epithelium-derived cytokine that belongs to the interleukin-7 (IL-7) cytokine family. Many such agents are known to those skilled in the art. Methods for determining whether a compound induces TSLP are known to those skilled in the art. For example, TSLP nucleic acid expression, TSLP protein expression or TSLP activity may be measured as described in more detail in US Patent Publication No. 2017 / 0246299, which is incorporated herein in its entirety. Non-limiting examples of TSLP inducers include retinoic acid, vitamin D analogs, polyinosinic-polycytidylic acid [poly(I:C) and other TLR3 ligands], FSL-1 (and other TLR2-TLR6 ligands), flagellin (and other TLRS ligands), beta2-adrenergic agonists, cAMP elevating agents (e.g., forskolin), fatty acids (heptanoic, octanoic, nonanoic, and decanoic acids), xylene, 1,2,4-trimethylbenzene, 12-O-tetradecanoylphorbol-13-acetate [TPA, tetradecanoylphorbol acetate, tetradecanoylphorbol acetate, and phorbol 12-myristate 13-acetate (PMA)], dibutyl phthalate (DBP), and diisononyl phthalate (DINP).
[0067] Retinoic acid is a metabolite of vitamin A (retinol) and an inducer of TSLP. It is known as tretinoin, vitamin A acid, ATRA, and all-trans retinoic acid.
[0068] In some embodiments, the TSLP inducer may be vitamin D or an analog thereof. Vitamin D refers to a group of fat-soluble secosteroids. Secosteroids are structurally very similar to steroids, except that two of the B-ring carbon atoms of the typical four steroid rings are bonded in steroids, whereas in secosteroids they are not. Examples include active vitamin D (or calcitriol) and vitamin D3, also known as cholecalciferol (a form of vitamin D produced in animal skin when light energy is absorbed by the precursor molecule 7-dehydrocholesterol).
[0069] Structurally modified derivatives of vitamin D may be referred to as vitamin D analogs. Vitamin D analogs may be modified to have improved bioavailability, solubility, improved stability and / or handling properties compared to unmodified versions. Prodrugs of vitamin D analogs are also contemplated. Any vitamin D analog capable of binding to the vitamin D receptor and inducing thymic stromal lymphopoietin (TSLP) may be suitable for the compositions described herein. There are many vitamin D analogs and they will be recognized by those skilled in the art. Non-limiting examples of suitable vitamin D analogs include 1,24-(OH)2D3 (calcitrol), 26,27-F fl-I , 25-(OH)2D3 (ST-630), I.alpha-(OH)D2, 1α-(OH)D3, 1,24-(OH)2D3 (TV-02), 22-oxacalcitriol (OCT), calcipotriol (MC 903), 1,25-(OH)2-16-ene-23-yne-D3 (Ro 23-7553), EB 1089, ED-71, PRI-2191, PRI-2205, cholecalciferol, ergocalciferol, calciferol, calcigex, calcitriol, doxercalciferol, hectorol, paricalcitol, rocaltrol, dovonex and zemplar, as well as other analogs described, for example, in U.S. Pat. No. 6,753,013. In the context of the present invention, the term "analog" is meant to include synthetic analogs and vitamin D metabolites.
[0070] In some embodiments, the vitamin D analog is calcipotriol (also known as calcipotriene or calcitren). Calcipotriene is a synthetic derivative of calcitriol, a form of vitamin D. It is used to treat psoriasis. Leo Pharma secured FDA approval in 1993 for calcipotriene topical ointment. Generic versions have been approved (GlenMark and Tolmar). Induction of the epidermis-derived cytokine, thymic stromal lymphopoietin (TSLP), protects against skin and breast cancer development 7~9 This protection is mediated by T cells that respond directly to TSLP. 7、8 Calcipotriene, a hypocalcemic vitamin D analog and inducer of TSLP, is an immunotherapy that has been used to treat breast cancer. 8 .
[0071] Innate immune activators The combination also involves the use of innate immune activators to activate antigen-presenting cells. Activators of the innate immune system include agonists of toll-like receptors (TLRs); STING agonists; or oncolytic viruses.
[0072] Several TLR agonists, e.g., agonists or activators of TLR7, TLR8 or TLR9, are known to those skilled in the art, including imiquimod (TLR7), resiquimod (TLR7), 852A {(N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide} (TLR7); motolimod (VTX-2337) (TLR8); CpG-ODN (TLR9), ODN2395 (TLR9); other TLR agonists that may be used include BCG (TLR 2 / 4 / 9); poly I:C / poly ICLC (TLR3); or MPL (TLR4). See, e.g., Mifsud et al., Front Immunol. 2014; 5:79; Adams, Immunotherapy. 2009 Nov 1; 1(6): 949-964; Kaczanowska et al., J Leukoc Biol. 2013 Jun; 93(6): 847-863. In some embodiments, the TLR agonist is not LPS. Imiquimod is a prescription drug that acts as an immune response modifier and is used to treat genital warts, superficial squamous basal cell carcinoma, and actinic keratosis. 3M obtained the first FDA approval in 1997 for imiquimod under the brand name Aldara. As of 2015, imiquimod is generic and available globally under a number of brands (Medicis, Apotex, Fougera, Glenmark, Perrigo Israel, Strides, Taro, and Tolmar). Imiquimod is the only topical agent that has been used experimentally to evaluate its potential as a treatment for breast cancer, skin metastases, extramammary Paget's disease, and melanoma. 1、4~6 Imiquimod is a toll-like receptor (TLR) 7 agonist that acts through activation of innate immune responses in the skin but does not directly activate adaptive immune cells. 4 .
[0073] As used herein, "STING agonist" refers to synthetic cyclic dinucleotides (CDNs) and other agonists of stimulator of interferon genes protein (STING), which can activate the cGAS-STING cytoplasmic DNA sensing pathway in cells and cause the activation of innate immune cells such as dendritic cells (e.g., DMXAA, MK-1454 and ADU-S100). DMXAA (5,6-dimethylxanthenone-4-acetic acid, ASA404 or vadimezan) is a STING agonist that functions as a vascular disrupting agent. In some embodiments, when a STING agonist is used, it is administered locally, e.g., by intralesional / intratumoral injection, as known in the art.
[0074] Oncolytic viruses (OV) are capable of replicating in cancer cells, but not in normal cells, leading to lysis of the tumor mass and activation of the innate immune system. OVs include talimogene laherparepvec (T-Vec) (Amgen); TBI-1401 (HF10) (Takara); G207 (MediGene); HSV1716 (Virtu Biologics); ADV / HSV-tk (Merck); LOAd703 (Lokon); CG0070 (Cold Genesys); ColoAd1 [Enadenotucirev] (PsiOxus); ONCOS-102 (Targovax Oy); DNX-2401 (DNAtrix); VCN-01 (VCN); Ad-MAGEA3 and MG1-MAGEA3 (Turnstone); NSC-CRAd-survivin-pk7 (Northwestern); Ad5-yCD / mutTKSR39rep-hIL12 (Henry Ford); Ad5-yCD / mutTKSR39rep-ADP (Henry Ford); MV-NIS (Mayo); MV-NIS (University of Arkansas); GL-ONC1 (Genelux); [Pexastimogene Devacirepvec] (Pexa-Vec) (Jennerex); Reolysin (Oncolytics); CVA21 [CAVATAK] (Viralytics); H-1PV (ParvOryx) (Oryx GmbH); PVSRIPO (Duke); and VSV-hIFNbeta-NIS (Mayo). See, e.g., Raja et al., Journal for ImmunoTherapy of Cancer (2018) 6:140; Marelli et al., Front Immunol. 2018; 9: 866.
[0075] Pharmaceutical Compositions and Methods of Administration The methods described herein include the use of pharmaceutical compositions that contain one or both of an agent that activates T cells by TSLP induction and an agent that activates innate immune cells as active ingredients. The methods may include the use of a single composition that contains both agents, or two compositions that each contain one of the agents. In some embodiments, these are the only active agents, i.e., no other active agents are included in the composition or method.
[0076] Pharmaceutical compositions generally include a pharmaceutically acceptable carrier. In this specification, the term "pharmaceutically acceptable carrier" includes physiological saline, solvent, dispersion medium, coating agent, antibacterial and antifungal agent, isotonic and absorption delaying agent, etc., that are compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the composition; however, in some embodiments, no other active compounds are used.
[0077] The compositions and methods do not include the use of cytotoxic drugs, e.g., as described in U.S. Patent Application Publication No. 2017 / 0246299, and / or do not include the use of anti-inflammatory drugs, e.g., NSAIDS such as diclofenac, and / or do not include the use of steroidal compounds, e.g., hydrocortisone valerate.
[0078] Pharmaceutical compositions are generally formulated to be compatible with the intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, intralesional / intratumoral, subcutaneous; transdermal or topical; transmucosal; or rectal or vaginal administration.
[0079] Methods for formulating suitable pharmaceutical compositions are known to those skilled in the art, see, for example, Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, NY). For example, solutions or suspensions used for parenteral, intradermal or subcutaneous application can contain the following components: sterile diluent such as water for injection, saline, fixed oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvent; antibacterial agent such as benzyl alcohol or methylparaben; antioxidant such as ascorbic acid or sodium bisulfite; chelating agent such as ethylenediaminetetraacetic acid; buffer such as acetate, citrate or phosphate, and agent for adjusting tonicity such as sodium chloride or dextrose. pH can be adjusted with acid or base, such as hydrochloric acid or sodium hydroxide. Parenteral preparations can be enclosed in ampoules, disposable syringes or glass or plastic multi-dose vials.
[0080] In some embodiments, the TLSP inducer is calcipotriol or another vitamin D analog, and when the method involves topical application, solvents that promote stability of the vitamin D / D analogs, such as those described in U.S. Pat. No. 6,753,013, non-limiting examples of which include: Alamol E [polyoxyethylene (15) stearyl ether]; Alamol DoA (diisooctyl ester of adipic acid); Arasorb 200 (polyoxyethylene-20-isohexadecyl ether); Eutanol G (2-octyldodecanol); Finsorb (isostearyl benzoate); Finsorb P (polyoxypropylene-15-benzoic acid stearyl ether); linear or branched C esters such as isopropyl myristate, isopropyl palmitate, isopropyl isostearate, isopropyl linolate, and isopropyl monooleate. 10 ~C 18Isopropyl esters of alkane or alkenoic acids; Miglyol 840 (propylene glycol diester of caprylic acid and capric acid); DPPG [propylene glycol dipelagonate]; and Procetyl AWS.
[0081] Pharmaceutical compositions suitable for injectable use may include sterile aqueous solutions (if water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and fluid to the extent that easy syringability exists. The composition should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier may be, for example, a solvent or dispersion medium containing water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it will be preferable to include isotonic agents in the composition, such as sugars, polyalcohols such as mannitol, sorbitol, sodium chloride. Prolonged absorption of the injectable composition can be brought about by including in the composition an agent that delays absorption, such as aluminum monostearate and gelatin.
[0082] Sterile injectable solution can be prepared by combining the required amount of active compound in suitable solvent with one or combination of the above-listed components, and then sterilizing by filtration if necessary.Generally, dispersion is prepared by incorporating active compound into sterile vehicle, which contains basic dispersion medium and other components required from above-listed.For the case of sterile powder for preparing sterile injectable solution, the preferred method of preparation is vacuum drying and freeze-drying, which produces powder of active ingredient + any additional desired components from the solution previously sterile filtered.
[0083] For administration by inhalation, the compounds can be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Patent No. 6,468,798.
[0084] The therapeutic compound described herein can be administered systemically via transmucosal or transdermal means.For transmucosal or transdermal administration, a penetrant suitable for the barrier to be permeated is used in the formulation.Such penetrants are generally known to those skilled in the art, and include, for example, surfactants, bile salts and fusidic acid derivatives for transmucosal administration.Transmucosal administration can be achieved by using nasal sprays or suppositories.For topical or transdermal administration, the active compound is generally formulated into ointments, salves, gels or creams known to those skilled in the art.
[0085] In some embodiments, the composition containing one or both agents for topical application may further contain a cosmetically acceptable carrier or vehicle and any optional ingredients.Some such cosmetically acceptable carriers, vehicles and optional ingredients are known to those skilled in the art, and include carriers and vehicles suitable for application to the skin (e.g., ointments, sunscreens, creams, emulsions, lotions, masks, serums, etc.), see, for example, U.S. Patent Nos. 6,645,512 and 6,641,824. In particular, optional ingredients that may be desirable include adsorbents, anti-acne actives, anti-caking agents, anti-steary agents, anti-foaming agents, anti-fungal actives, anti-inflammatory actives, anti-microbial actives, antioxidants, antiperspirant / deodorant actives, anti-skin atrophy actives, antiviral agents, anti-wrinkle actives, artificial tanning agents and accelerators, astringents, barrier repair agents, binding agents, buffering agents, bulking agents, chelating agents, colorants, pigments, enzymes, essential oils, film formers, flavors, fragrances, moisturizers, and the like. These include, but are not limited to, moisturizers, hydrocolloids, light diffusers, nail polish, opacifiers, optical brighteners, optical modifiers, particulates, fragrances, pH adjusters, sequestrants, skin conditioning / moisturizing agents, skin feel modifiers, skin protectants, skin sensates, skin treatment agents, skin exfoliants, skin lightening agents, skin soothing and / or healing agents, skin thickening agents, sunscreen actives, topical anesthetics, multivitamins, and combinations thereof. In some embodiments, the composition comprises one or more of benzyl alcohol, cetyl alcohol, glycerin, isostearic acid, methylparaben, polysorbate 60, propylparaben, purified water, sorbitan monostearate, stearyl alcohol, white petrolatum, and / or xanthan gum.
[0086] The compositions may also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal or vaginal delivery. Such suppositories may be particularly used to treat symptoms associated with lesions or tumors present in the reproductive or digestive tract.
[0087] The pharmaceutical compositions can be included in a container, packet, or dispenser together with instructions for administration.
[0088] Topical compositions containing one or both of the agent that activates T cells by TSLP induction and the innate immune cell activation agent, e.g., imiquimod and / or calcipotriene and / or retinoic acid, are suitable for safe and effective use within a range of concentrations. Thus, the amount of the topically active agent in the compositions described herein is between 5 μg / mL and 2000 μg / mL, e.g., 25 μg / mL, 100 μg / mL, 500 μg / mL 1000 μg / mL, 1500 μg / mL or 2000 μg / mL. In certain embodiments, calcipotriene (0.005% μg / mL) and about 5% μg / mL to about 3.75% μg / mL imiquimod are used in combination. In other specific embodiments, retinoic acid is administered topically in cream or gel form at a dose of 0.01%, 0.025%, 0.04%, 0.05% or 0.1%. The dosing schedule, i.e., dosing regimen, for this use will depend on a variety of factors, including the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical condition, age, etc. At a minimum, dosing should continue for at least one month.
[0089] Topical compositions should also be suitable for safe and effective use within a pH range. Thus, the pH of the topical compositions described herein is between 6.0 and 7.5.
[0090] In some embodiments, the formulations described herein are suitable for topical administration.The methods described herein are ideally suited for increasing the amount of at least one agent in the epidermis, or epidermis and dermis, in the skin area of a subject.The topical compositions described herein can be administered in a dosage suitable for entering the bloodstream.Therefore, the agent can be administered locally as an adjuvant before or at the same time as direct systemic administration into the bloodstream.
[0091] The formulation may conveniently be in the form of a unit dosage form and may be prepared by any method known in the art of pharmacy. The formulation may be mixed with non-toxic pharma- ceutically acceptable excipients suitable for manufacture. The formulation may include one or more diluents, emulsifiers, preservatives, buffers, excipients, etc., and may be provided in such forms as solutions, ointments, pastes, emulsions, sprays, creams, lotions, slurries, suspensions, foams, controlled release formulations, gels, patches, implants, water-oil bilayer compositions, water-oil powder triple layer compositions, serums, powders, mousses, hydrogels, disposable applicators, etc., suitable for topical administration to a patient.
[0092] The formulations described herein may include a dermatologically acceptable carrier (also referred to herein simply as "carrier") for the composition. The phrase "dermatologically acceptable carrier" as used herein means that the carrier is suitable for topical application to the hair / scalp, has good aesthetic properties, is compatible with the ETA in the composition, and will not raise any unreasonable safety or toxicity concerns. A suitable carrier is selected to yield the desired product form. Additionally, the solubility or dispersibility of the ingredients may affect the form and characteristics of the carrier. In some embodiments, the carrier is present at a level of about 50% to about 99%, about 60% to about 98%, about 70% to about 98%, or alternatively, about 80% to about 95% by weight of the composition.
[0093] The carrier can be in various forms. Non-limiting examples include simple solutions (e.g., water-soluble, organic-soluble or oil-based), emulsions, and solid dosage forms (e.g., gels, sticks, flowable solids or amorphous materials). In certain embodiments, the dermatologically acceptable carrier is in the form of an emulsion. Emulsions can generally be classified as having a continuous aqueous phase (e.g., oil-in-water and water-in-oil-in-water) or a continuous oil phase (e.g., water-in-oil and oil-in-water-in-oil). The oil phase of the present invention can include silicone oils, non-silicone oils such as hydrocarbon oils, esters, ethers, etc., and mixtures thereof.
[0094] The aqueous phase comprises water, for example demineralized water or distilled water.Other acceptable carriers that can be used for the aqueous carrier include, but are not limited to, alcoholic compounds, such as ethanol.According to some embodiments, the composition comprises alcohol, dipropylene glycol and / or water.
[0095] The emulsion may further comprise an emulsifier. The composition may comprise any suitable percentage of emulsifier to sufficiently emulsify the carrier. Suitable weight ranges include about 0.1% to about 10% by weight or about 0.2% to about 5% by weight of emulsifier based on the weight of the composition. The emulsifier may be nonionic, anionic, or cationic. Suitable emulsifiers are disclosed, for example, in U.S. Pat. Nos. 3,755,560 and 4,421,769 and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986), which are incorporated herein by reference in their entirety. Suitable emulsions may have a wide range of viscosities depending on the desired product form. Non-limiting examples of emulsifiers include glyceryl stearate, polysorbate 60, and the PEG-6 / PEG-32 / glycerol stearate mixture sold by Gattefosse under the name Trefose®. The emulsion may contain a fatty phase, which may range between about 5% and about 80% by weight of the composition (e.g., between about 5% and about 50%). Any of the emulsions described herein may contain one or more agents selected from the group of oils, waxes, emulsifiers, and coemulsifiers. Examples of oils, waxes, emulsifiers, and coemulsifiers used in the formulation are well known to those skilled in the art. The emulsifiers and coemulsifiers may be present in the composition in a proportion of 0.3% to about 30% by weight of the composition (e.g., between about 0.5% to about 20%). The emulsion may contain lipid vesicles.
[0096] Topical compositions may be formulated with other agents, including but not limited to other agents for the treatment of skin cancer, inflammatory diseases, benign neoplasms (e.g., hemangiomas), pigmentary disorders, diagnostic agents, and cosmetic agents. Such formulations may be configured to control-release multiple agents at different rates, either sequentially or simultaneously.
[0097] Other agents that may be administered together or subsequently include, but are not limited to, antimicrobial agents, antiseptics, and analgesics. Such agents may be administered sequentially (e.g., after prior administration of the topical composition) or simultaneously, e.g., in a dual release dosage formulation.
[0098] In some embodiments, the method comprises administering a treatment described herein daily, e.g., once or twice daily, for at least 2, 3, 4, 5, 6, 7, 8 9, 10, 11, 12, 13 or 14 days, e.g., 4 days, and surgically removing any remaining lesions, e.g., after 7, 10, 12, 14, 21 or 28 days, e.g., after 7 to 28, 14 to 21 days, of treatment. In some embodiments, the method comprises repeating the treatment regimen at least 2, 3, 4, 5, 6 or more times prior to optional surgical intervention. In some embodiments, the treatment regimen comprises administering a treatment described herein daily, e.g., once or twice daily, for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days, e.g., 4 days, followed by a rest interval between the treatment intervals, e.g., of at least 7, 10, 12, 14, 21 or 28 days, e.g., 7 to 28, 14 to 21 days.
[0099] The present invention is further described by the following illustrative, non-limiting examples that provide a better understanding of the present invention and its many advantages. EXAMPLES
[0100] The following examples illustrate some embodiments and aspects of the present invention. It will be apparent to those skilled in the art that various modifications, additions, substitutions, etc. may be made without altering the spirit or scope of the present invention, and such modifications and changes are encompassed within the scope of the present invention as defined in the following claims. The following examples do not limit the invention in any way.
[0101] [Example 1] Compositions Comprising Calcipotriene and Imiquimod Exhibit Antitumor Efficacy The inventors have demonstrated that T cell activating agents (e.g., calcipotriene and retinoic acid) 10 ) and innate immune cell activating drugs (e.g., TLR agonists such as imiquimod and DMXAA 11 We hypothesized that combinations of calcipotriene plus imiquimod, calcipotriene plus DMXAA, and retinoic acid plus imiquimod could result in potent antitumor immunity against cutaneous malignancies. To test this hypothesis, we investigated the efficacy of calcipotriene plus imiquimod, calcipotriene plus DMXAA, and retinoic acid plus imiquimod in inhibiting the growth of cutaneous breast cancer and melanoma.
[0102] To test the hypothesis that the combination of a T cell activating drug (i.e., calcipotriene) and an innate immune cell activating drug (i.e., imiquimod) may result in potent antitumor immunity against cutaneous malignancies, we investigated the efficacy of calcipotriene plus imiquimod in inhibiting the growth of cutaneous mammary carcinomas in mice.
[0103] Breast cancer cells were obtained from PyMTtg mice, which develop idiopathic breast cancer that resembles human luminal breast cancer. 12 Breast cancers from PyMTtg mice were harvested before the tumors reached 2 cm in diameter. The tumors were excised and dissociated into a single cell suspension. Breast cancer cells were cultured at 1 × 10 per 100 μL in a 1:1 ratio of RPMI and Matrigel Membrane Matrix (Corning). 6 The recipient mice were shaved in the groin area prior to cancer cell injection. On day 0, the cells were resuspended at a concentration of 1 × 10 6Single cells were injected subcutaneously. Once tumor size reached 5 mm in diameter, topical treatments were applied. Mice were divided into four groups and treated with either calcipotriene (80 nmol) or the carrier ethanol (EtOH) directly at the tumor site. Following calcipotriene or EtOH treatment, the tumor site was also treated with topical application of either imiquimod 5% cream or moisturizing cream (control cream). Calcipotriene / EtOH and imiquimod / control cream treatments were reapplied once more after 3 days (Figure 1A). Animals were monitored daily and tumors were measured over time to determine the effect of topical treatments on breast cancer growth. At harvest, tumors were weighed and tumor-infiltrating T cells were profiled using flow cytometry.
[0104] Two applications of the calcipotriene + imiquimod combination resulted in a significant inhibition of the growth of cutaneous breast tumors compared to EtOH + control cream-treated breast tumors (p = 0.011, Figure 1B-D). Neither calcipotriene nor imiquimod applied alone showed a significant effect on breast cancer growth after two applications (Figure 1B-D). Surprisingly, the calcipotriene + imiquimod combination caused a significant induction of T cell (CD3+CD19-) infiltration (Figure 1E) and proliferation of CD4+ and CD8+ tumor-infiltrating T lymphocytes (Ki67+) (Figure 1F) within the treated tumors. These findings highlight the role of antitumor immunity in mediating the effect of calcipotriene + imiquimod treatment on breast cancer.
[0105] [Example 2] Calcipotriene plus DMXAA blocked melanoma progression. Melanoma cells (B16-F10, ATCC, Manassas, VA) were cultured at 2 × 10 per 100 μL of DMEM (Corning) in a 1:1 ratio on day 0. 5Mice were subcutaneously injected with 100 μg DMXAA in 100 μL saline. The flanks of recipient mice were shaved prior to cancer cell injection. When tumor size reached 5 mm in diameter, local treatment with calcipotriene or EtOH was initiated along with intraperitoneal (IP) injection of DMXAA (mouse STING agonist, 5,6-dimethylxanthenone-4-acetic acid, ASA404 or vadimezan) or saline. Mice were divided into four groups and treated locally with either calcipotriene (40 nmol) or the carrier ethanol (EtOH) directly at the tumor site. After calcipotriene or EtOH (control) treatment, mice were IP injected with either 400 μg DMXAA in 100 μL saline or saline alone (control). Calcipotriene / EtOH and DMXAA / saline treatments were reapplied two more times (Figure 2A). Animals were monitored daily and tumors were measured over time to determine the effect of treatment on melanoma growth. At harvest, tumors were weighed and tumor-infiltrating T cells were profiled using flow cytometry.
[0106] Three applications of the calcipotriene + DMXAA combination resulted in significant inhibition of cutaneous melanoma growth compared to EtOH + saline treated melanomas (p = 0.019, Figures 2B-D). Calcipotriene alone showed efficacy in inhibiting melanoma growth, whereas DMXAA alone showed no significant effect on melanoma progression after three applications (Figures 2B-D). The calcipotriene + DMXAA combination caused a significant induction of T cell (CD3+CD19-) infiltration (Figure 2E) and proliferation of CD4+ and CD8+ tumor infiltrating T lymphocytes (Ki67+) (Figure 2F) within treated tumors. The induction was absent in the calcipotriene alone, DMXAA alone and EtOH + saline control groups. These findings demonstrate that antitumor immunity mediated the effect of calcipotriene + DMXAA treatment on melanoma.
[0107] [Example 3] Calcipotriene plus imiquimod and retinoic acid plus imiquimod inhibited melanoma growth In a complementary set of experiments, B16-F10 melanoma cells were injected subcutaneously into the flank of mice. Once tumors were palpable, topical treatments were applied. Mice were divided into five groups and treated with either calcipotriene (20 nmol), retinoic acid (20 nmol) or the carrier ethanol (EtOH) directly at the tumor site. Following treatment with either calcipotriene, retinoic acid or EtOH, the tumor site was also treated with topical application of either imiquimod 5% cream or moisturizing cream (control cream). Calcipotriene / retinoic acid / EtOH and imiquimod / control cream treatments were reapplied two more times at 3-day intervals (Figure 3A). Animals were monitored daily and tumors were measured over time to determine the effect of topical treatments on melanoma growth. At harvest, tumors were photographed and their weights recorded.
[0108] Triplicate applications of the calcipotriene + imiquimod and retinoic acid + imiquimod combinations resulted in significant inhibition of melanoma tumor growth compared to monotherapy with calcipotriene, retinoic acid or imiquimod as demonstrated by macroscopic images, tumor volume over time and tumor weight at harvest (p<0.05, Figure 3B-D). These findings highlight the role of antitumor immunity in mediating the effects of calcipotriene + imiquimod and retinoic acid + imiquimod treatments on melanoma.
[0109] [Example 4] The combination of calcipotriene and imiquimod improves EMPD lesions in patients To determine the efficacy of the calcipotriene + imiquimod combination in treating EMPD in patients, two male EMPD patients were treated with topical calcipotriene 0.005% ointment in the morning and imiquimod 5% cream at night for 4 days, and residual lesions were surgically excised 14-21 days after treatment (Figure 4A). The extent of disease was documented by clinical imaging before treatment and at the time of surgery, and interestingly, 4 days of treatment with the calcipotriene + imiquimod combination resulted in significant inflammation (i.e., immune activation) at the EMPD lesion sites, which subsided 2 weeks after treatment. Importantly, this treatment resulted in a significant reduction in lesion size by the time of surgery, which was confirmed by a reduction in negative surgical margins on the excised lesions (yellow dotted line, Figure 4B). reference
[0110] All patents, patent applications, and publications mentioned in this specification are herein incorporated by reference to the same extent as if each individual patent and publication was specifically and individually indicated to be incorporated by reference.
[0111] [Table 1-1]
[0112] [Table 1-2]
[0113] [Table 1-3]
Claims
1. 1. A medicament for use in treating a proliferative disorder in the skin of a subject, comprising (i) calcipotriene, and (ii) imiquimod or DMXAA.
2. The pharmaceutical composition of claim 1, which does not include administration of a cytotoxic drug.
3. 3. The method of claim 1 or 2, for administering (i) and (ii) directly to the site of proliferation in the skin of a subject.
4. 4. The pharmaceutical of any one of claims 1 to 3, wherein the proliferative disorder in the skin is a non-keratinocyte carcinoma, and optionally the non-keratinocyte carcinoma is melanoma, extramammary Paget's disease or breast cancer metastasis, or optionally the non-keratinocyte carcinoma is not squamous cell carcinoma ("SCC"), basal cell carcinoma ("BCC") or keratinocyte carcinoma.
5. The method of claim 3 or 4, wherein the site of the proliferative disorder in the skin is a tumor.
6. The method of any one of claims 3 to 5, wherein the site of a proliferation disorder in the skin comprises a metastasis within the chest wall of the subject.
7. The pharmaceutical composition according to any one of claims 1 to 6, wherein (i) and (ii) are administered simultaneously or sequentially.
8. The method according to any one of claims 1 to 7, wherein a single composition comprising (i) and (ii) is administered.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein one or both of (i) and (ii) are administered locally.
Citation Information
Patent Citations
Composition and method for treating skin conditions
US20120115821A1
